Previous 10 | Next 10 |
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer...
Trading in Bausch Health Companies ( BHC ) was briefly halted Thursday morning and is currently down 50 % after a Delaware federal court judge issued an oral order on patent litigation over Xifaxan. Judge Richard Andrews has directed Bausch ( BHC ) subsidiary S...
Alnylam Pharmaceuticals ( NASDAQ: ALNY ) stock is trading in the green July 28 despite Q2 results missing street estimates, but the RNAi therapy maker has reiterated its FY22 outlook. Non-GAAP net loss widened to -$245.83M, compared to -$153.05M in Q1 2021. Tota...
Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q2 Non-GAAP EPS of -$2.03 misses by $0.69 . Revenue of $224.82M (+1.9% Y/Y) misses by $31.24M . Cash, cash equivalents and marketable securities were $2.11 billion as of June 30, 2022, compared to $2.44 bi...
− Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® (33% Growth vs. Same Period Last Year) – − Received FDA Approval of AMVUTTRA™ (vutrisiran) f...
Alnylam Pharmaceuticals ( NASDAQ: ALNY ) is scheduled to announce Q2 earnings results on Thursday, July 28th, before market open. The consensus EPS Estimate is -$1.34 (-3.1% Y/Y) and the consensus Revenue Estimate is $256.06M (+16.1% Y/Y). Over the last 2 years, ALNY ...
Alnylam Pharmaceuticals ( NASDAQ: ALNY ), a biotech focused on RNAi therapeutics, announced on Wednesday its plans to pursue a cardiometabolic candidate based on mutations in the INHBE gene after a study led to supportive data. The development plan follows the research of ...
- Publication in Nature Communications Reports that People with Loss of Function Mutations in the INHBE Gene Have Reduced Abdominal Fat, a Favorable Metabolic Profile, and are at Lower Risk of Cardiovascular Disease and Type 2 Diabetes - - Alnylam to Pursue INHBE as a Therapeu...
A committee of the European Medicines Agency ( EMA ) recommended the approval of Alnylam Pharmaceuticals' ( NASDAQ: ALNY ) RNAi therapy Amvuttra (vutrisiran) to treat hereditary transthyretin-mediated (hATTR) amyloidosis in adults patients with stage 1 or sta...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...